LIVERFASt outperforms FIB-4, in sequential combination with VCTE, for identifying ≥F3 stages in MASLD including T2DM
LIVERFASt outperforms FIB-4, in sequential combination with VCTE, for identifying ≥F3 stages in MASLD including T2DM
Correlations between LIVERFASt, MRE for fibrosis assessment and ICFF for steatosis assessment in MASLD patients
Correlations between LIVERFASt, MRE for fibrosis assessment and ICFF for steatosis assessment in MASLD patients
Diagnostic performance of LIVERFASt as a non-invasive liver fibrosis test: data from three cohorts (JGLD manuscript)
Diagnostic performance of LIVERFASt as a non-invasive liver fibrosis test: data from three cohorts (JGLD manuscript)
Combination of LF and LSM using Fibroscan outperforms FIB-4 and LSM in patients with T2D
Combination of LF and LSM using Fibroscan outperforms FIB-4 and LSM in patients with T2D
Association between Psoriasis severity and steatosis measured by LIVERFASt
Association between Psoriasis severity and steatosis measured by LIVERFASt
Comparison of prevalence of advanced fibrosis using LiverSTAT or FIB-4 combined with LSM/VCTE in a prospective chronic liver disease cohort (Mongolia)
Comparison of prevalence of advanced fibrosis using LiverSTAT or FIB-4 combined with LSM/VCTE in a prospective chronic liver disease cohort (Mongolia)
Combination of LIVERSTAT and Fibroscan-LSM outperforms FIB-4 and LSM for MASLD Advanced Fibrosis (F3F4) — multicenter
Combination of LIVERSTAT and Fibroscan-LSM outperforms FIB-4 and LSM for MASLD Advanced Fibrosis (F3F4) — multicenter
LIVERFASt identifies advanced (F3F4) and clinically significant fibrosis (F2-F4) especially well with Fibroscan in MASLD patients
LIVERFASt identifies advanced (F3F4) and clinically significant fibrosis (F2-F4) especially well with Fibroscan in MASLD patients
Comparison of two non-invasive models for advanced fibrosis detection in T2D and MASLD using LiverSTAT, FIB-4 and LSM (Saudi Arabia)
Comparison of two non-invasive models for advanced fibrosis detection in T2D and MASLD using LiverSTAT, FIB-4 and LSM (Saudi Arabia)
Evaluation of LIVERFASt for staging fibrosis in MASLD patients in NIDDK studies using liver biopsy
Evaluation of LIVERFASt for staging fibrosis in MASLD patients in NIDDK studies using liver biopsy